News
Eli Lilly's obesity drugs delivered 38% revenue growth in the second quarter; but its oral GLP-1 candidate fell short, ...
Eli Lilly Vs. Novo Nordisk: Correction Overly Done - GLP-1 Market Leadership/ Robust Pipelines Ahead
Novo Nordisk's (NVO) corrections amid AI market rotation might be an opportunity, due to GLP-1 market leadership & balanced ...
14h
Indy100 on MSNIs Trump to blame for the UK’s 170% Mounjaro price surge?
The cost of Mounjaro, a popular weight-loss injection, is set to rise sharply in the UK – from £122 to £330 – a 170 per cent ...
8h
TipRanks on MSNEli Lilly’s Stock Soars Amid Promising Trials
Eli Lilly & Co ( ($LLY) ) has risen by 10.63%. Read on to learn why. Eli Lilly & Co has seen a notable increase in its stock price, rising ...
The former This Morning presenter, 63, has long been open about her struggles with her weight, which have seen her fluctuate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results